Saturday, October 16, 2021

CDC vaccine experts punt on Johnson & Johnson COVID-19 vaccine guidance, extending the pause


U.S. vaccine experts have identified three potential options for Johnson & Johnson’s COVID-19 vaccine in the U.S. going forward. But while they wait for more data, the shot’s nationwide pause will continue.

Moving forward, the United States could continue the vaccine’s use with a safety warning, or it could put age and gender restrictions on the product. Officials could also discontinue use of the shot entirely, experts at the CDC’s Advisory Committee on Immunization Practices said during a Wednesday meeting. 

For now, though, the group has decided to punt on any decisions and collect more data. The group plans to meet in the coming week or two for a new session.

The meeting came after U.S. officials on Tuesday recommended a pause to the shot’s rollout after rare but serious blood clots in six people after vaccination. One died and one was in critical condition, officials said Tuesday. About 7 million people had been vaccinated before the pause. 

Of the six CVST cases in the U.S., all have been white women between the ages of 18 and 48. The clots have occurred between 6 and 13 days after vaccinations. More cases could surface because around half of the J&J doses administered were in the last two weeks, officials said.

With the data the experts currently have, it’s impossible to come to conclusions about the shot’s safety, Sara Oliver of the CDC said at the Wednesday meeting.

Meanwhile, there have been no CVST cases reported among the 97.9 million doses of the Pfizer vaccine and 84.7 million doses of the Moderna vaccine administered so far, the CDC said.

RELATED: Feds call halt to Johnson & Johnson COVID-19 vaccine rollout after ‘extremely rare’ blood clot cases

As the group prepares for its next meeting, a number of factors could inform its ultimate decision. Those include the positive risk-benefit profile of the Pfizer and Moderna mRNA vaccines, plus available supply of those shots, and the available J&J doses on deck. The FDA, which issued an emergency use authorization for the product, could also weigh in.

In the end, the experts may not make their decision based on the risk of J&J’s vaccine versus COVID, Oliver said. It could also depend on the risk-benefit profiles of the mRNA and J&J shots.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...